...
首页> 外文期刊>Journal of Virological Methods >Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
【24h】

Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.

机译:比较豚鼠对不同口蹄疫转基因疫苗的免疫应答。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The P12A3C gene from FMDV (serotype O) encoding the capsid precursor protein, and the highly immunogenic gene FHG, which encodes multiple epitopes of FMDV capsid proteins, were inserted into eukaryotic expression vectors to compare different candidate genetically engineered vaccines for foot-and-mouth disease (FMD). A modified live pseudorabies virus (MLPRV) was also used to deliver P12A3C. Guinea pigs were inoculated intramuscularly with the candidate vaccines to compare the ability to elicit immunity of the DNA vector and a live viral vector. An indirect enzyme-linked immunosorbent assay (iELISA), virus-neutralization test and lymphoproliferation assay were used to detect antibody and cellular responses. The group immunized with P12A3C delivered by MLPRV produced significantly greater antibody and cellular responses indicating that MLPRV has a greater ability to mediate exogenous gene delivery than the plasmid DNA vector. Comparison of the immune responses induced by P12A3C and FHG, which were both mediated by DNA plasmids, showed that FHG and P12A3C elicited similar cellular responses, while P12A3C induced higher antibody levels, suggesting that P12A3C is a more powerful immunogen than FHG. In challenge experiments, guinea pigs vaccinated with P12A3C delivered by MLPRV were protected fully from FMDV challenge, whereas guinea pigs vaccinated with P12A3C or FHG delivered by DNA plasmid were only protected partially. This study provides a basis for future construction of a genetically engineered vaccine for FMDV.
机译:将来自FMDV(O型)的衣壳前体蛋白编码的P12A3C基因和编码FMDV衣壳蛋白多个表位的高度免疫原性基因FHG插入真核表达载体中,以比较口蹄疫的不同候选基因工程疫苗疾病(FMD)。改良的活伪狂犬病病毒(MLPRV)也用于递送P12A3C。用候选疫苗肌内接种豚鼠,以比较引起DNA载体和活病毒载体免疫力的能力。间接酶联免疫吸附试验(iELISA),病毒中和试验和淋巴增殖试验用于检测抗体和细胞反应。用MLPRV递送的P12A3C免疫的组产生明显更高的抗体和细胞应答,表明MLPRV介导外源基因递送的能力比质粒DNA载体更高。比较均由DNA质粒介导的P12A3C和FHG诱导的免疫应答,结果表明FHG和P12A3C引发了相似的细胞应答,而P12A3C诱导了更高的抗体水平,表明P12A3C比FHG具有更强大的免疫原性。在攻击实验中,接种了MLPRV的P12A3C疫苗的豚鼠受到了FMDV的完全保护,而接种了DNA质粒的P12A3C或FHG疫苗的豚鼠仅受到了部分保护。该研究为将来构建FMDV的基因工程疫苗提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号